Published in J Immunol on January 01, 1969
N-formylmethionyl peptides as chemoattractants for leucocytes. Proc Natl Acad Sci U S A (1975) 9.24
Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest (1977) 5.16
Mechanisms of lysosomal enzyme release from human leukocytes: microtubule assembly and membrane fusion induced by a component of complement. Proc Natl Acad Sci U S A (1973) 4.58
A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J Exp Med (1972) 3.93
Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Clin Invest (1971) 3.61
Platelet factor 4 is chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A (1981) 3.03
Polymorphonuclear leukocyte chemotactic activity in rabbit serum and Guinea pig serum treated with immune complexes: evidence for c5a as the major chemotactic factor. Infect Immun (1970) 3.01
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Stimulation of human neutrophil leukocyte aerobic glucose metabolism by purified chemotactic factors. J Clin Invest (1974) 2.90
Chemotactic peptide receptor modulation in polymorphonuclear leukocytes. J Cell Biol (1980) 2.72
Release of histamine from rat mast cells by the complement peptides C3a and C5a. Immunology (1975) 2.62
Interaction of leukocyte chemotactic factors with the cell surface. I. Chemotactic factor-induced changes in human granulocyte surface charge. J Clin Invest (1975) 2.40
Chemotaxis by polymorphonuclear leukocytes. J Cell Biol (1978) 2.20
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Enhancement of random migration and chemotactic response of human leukocytes by ascorbic acid. J Clin Invest (1974) 1.81
Generation of C5a by phagocytic cells. Am J Pathol (2002) 1.72
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Structural determinants of the eosinophil: chemotactic activity of the acidic tetrapeptides of eosinophil chemotactic factor of anaphylaxis. J Exp Med (1976) 1.61
Quantification of mouse macrophage chemotaxis in vitro: role of C5 for the production of chemotactic activity. Infect Immun (1975) 1.57
Chemotactic activity generated from the fifth component of complement by plasma kallikrein of the rabbit. J Exp Med (1981) 1.57
C3a is a chemotaxin for human eosinophils but not for neutrophils. I. C3a stimulation of neutrophils is secondary to eosinophil activation. J Exp Med (1995) 1.36
Urate crystal-induced chemotactic factor: isolation and partial characterization. J Clin Invest (1976) 1.34
Polymorphonuclear leucocyte chemotaxis in patients with bacterial infections. Br Med J (1971) 1.30
A unique complement derived chemotactic factor for tumor cells. Proc Natl Acad Sci U S A (1975) 1.23
Bronchial biopsy evidence for leukocyte infiltration and upregulation of leukocyte-endothelial cell adhesion molecules 6 hours after local allergen challenge of sensitized asthmatic airways. J Clin Invest (1994) 1.22
Initial characterization of a peripheral blood mononuclear cell chemoattractant derived from cultured arterial smooth muscle cells. Am J Pathol (1984) 1.19
Platelets, fibroblasts, and inflammation: tissue reactions to platelets injected subcutaneously. Am J Pathol (1980) 1.17
The natural mediator for PMN emigration in inflammation. II. Common antigenicity of leucoegresin with immunoglobulin G. Immunology (1971) 1.17
Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli. Proc Natl Acad Sci U S A (1985) 1.17
Chemotaxis of human basophil leucocytes. Clin Exp Immunol (1972) 1.14
Acute immunologic arthritis in rabbits. J Clin Invest (1972) 1.14
Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med (1983) 1.13
Potentiation of the anaphylatoxins in vivo using an inhibitor of serum carboxypeptidase N (SCPN). I. Lethality and pathologic effects on pulmonary tissue. Am J Pathol (1983) 1.10
Selective attraction of eosinophils and synergism between eosinophil chemotactic factor of anaphylaxis (ECF-A) and a fragment cleaved from the fifth component of complement (C5a). Immunology (1973) 1.07
The natural mediator for PMN emigration in inflammation. I. Purification and characterization of leucoegresin from Arthus skin site. Immunology (1971) 1.07
Interferon-gamma (IFN-gamma) and macrophage inflammatory proteins (MIP)-1 and -2 are involved in the regulation of the T cell-dependent chronic peritoneal neutrophilia of mice infected with mycobacteria. Clin Exp Immunol (1992) 1.02
Stimulation of tubulin tyrosinolation in rabbit leukocytes evoked by the chemoattractant formyl-methionyl-leucyl-phenylalanine. J Cell Biol (1981) 1.02
CD4+ T cells are required for antigen-specific recruitment of neutrophils by BCG-immune spleen cells. Immunology (1992) 0.98
Cathepsin g is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. Am J Pathol (2007) 0.96
Chemotactic activity derived from interaction of factors D and B of the properdin pathway with cobra venom factor or C3B. J Clin Invest (1975) 0.94
Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. Proc Natl Acad Sci U S A (1983) 0.94
Inhibition of cathepsin D-type proteinase of macrophages by pepstatin, a specific pepsin inhibitor, and other substances. Infect Immun (1973) 0.94
Modulation of human eosinophil polymorphonuclear leukocyte migration and function. Am J Pathol (1976) 0.93
Substrates of the plasminogen activator protease of Yersinia pestis. Adv Exp Med Biol (2012) 0.92
Hereditary deficiency of the fifth component of complement in man. II. Biological properties of C5-deficient human serum. J Clin Invest (1976) 0.92
Chemotactic activity generated in human serum from the fifth component of complement by hydrogen peroxide. Am J Pathol (1984) 0.91
Cytokine-induced neutrophil chemoattractant in a rat model of lipopolysaccharide-induced acute lung injury. Inflammation (1999) 0.90
Inhibition of neutrophil chemotaxis in association with experimental angioedema in patients with cold urticaria: a model of chemotactic deactivation in vivo. Clin Exp Immunol (1979) 0.89
Cardiac failure in C5-deficient A/J mice after Candida albicans infection. Infect Immun (2006) 0.88
Attachment of human C5a des Arg to its cochemotaxin is required for maximum expression of chemotactic activity. J Clin Invest (1986) 0.88
Chemotactic activity generated by staphylococcal enterotoxin B. Infect Immun (1971) 0.85
Kidney injury accelerates cystogenesis via pathways modulated by heme oxygenase and complement. J Am Soc Nephrol (2012) 0.84
Chemotactic factors released in culture by intact developing and healing skin lesions produced in rabbits by the irritant sulfur mustard. Inflammation (1997) 0.82
The role of phagocyte function in resistance to infection. Calif Med (1971) 0.80
Effect on the human complement system of the major non-steroidal anti-inflammatory drugs: aspirin, indomethacin, phenylbutazone, oxyphenbutazone and sulindac. Clin Exp Immunol (1983) 0.79
Cell and tissue damage through antigen-antibody complexes. Calif Med (1969) 0.79
Polymorphonuclear neutrophil chemotaxis under aerobic and anaerobic conditions. Infect Immun (1978) 0.78
Pre-neutralization of C5a-mediated effects by the monoclonal antibody 137-26 reacting with the C5a moiety of native C5 without preventing C5 cleavage. Clin Exp Immunol (2003) 0.78
Systematic Review of Pharmacological Properties of the Oligodendrocyte Lineage. Front Cell Neurosci (2016) 0.78
Purification and properties of the cathepsin D types proteinase from beef and rabbit lung and its identification in macrophages. Infect Immun (1973) 0.76
Oxytocin ameliorates the immediate myocardial injury in heart transplant through down regulation of the neutrophil dependent myocardial apoptosis. Heart Views (2014) 0.76
Differential contribution of chemotaxins and opsonins to neutrophil-mediated killing of Schistosoma mansoni larvae. Infect Immun (1986) 0.75
Antiproteases modulate bronchial epithelial cell responses to endotoxin. Am J Pathol (1995) 0.75
Further studies on the chemotactic factor of complement and its formation in vivo. Immunology (1966) 7.59
Bacterial factors chemotactic for polymorphonuclear leukocytes. Am J Pathol (1968) 5.77
Endothelial cell gene expression of a neutrophil chemotactic factor by TNF-alpha, LPS, and IL-1 beta. Science (1989) 4.99
A plasmin-split fragment of C'3 as a new chemotactic factor. J Exp Med (1967) 4.94
The deactivation of rabbit neutrophils by chemotactic factor and the nature of the activatable esterase. J Exp Med (1968) 4.79
Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol (1982) 4.38
Leukotactic factor produced by sensitized lymphocytes. Science (1969) 3.95
Mechanisms of the inhibition of chemotaxis by phosphonate esters. J Exp Med (1967) 3.87
C5 chemotactic fragments produced by an enzyme in lysosomal granules of neutrophils. J Immunol (1970) 3.75
Cellular and molecular regulation of tumor necrosis factor-alpha production by pentoxifylline. Biochem Biophys Res Commun (1988) 3.63
Adhesion molecules and inflammatory injury. FASEB J (1994) 3.53
Acute immunologic pulmonary alveolitis. J Clin Invest (1974) 3.53
The isolation and partial characterization of neutrophil chemotactic factors from Escherichia coli. J Immunol (1975) 3.50
Intravascular activation of complement and acute lung injury. Dependency on neutrophils and toxic oxygen metabolites. J Clin Invest (1982) 3.49
Vascular endothelial-cadherin is an important determinant of microvascular integrity in vivo. Proc Natl Acad Sci U S A (1999) 3.49
Purification and identification of formyl-methionyl-leucyl-phenylalanine as the major peptide neutrophil chemotactic factor produced by Escherichia coli. J Biol Chem (1984) 3.32
Length of uninterrupted CGG repeats determines instability in the FMR1 gene. Nat Genet (1994) 3.22
The production by antigen-stimulated lymphocytes of a leukotactic factor distinct from migration inhibitory factor. Cell Immunol (1970) 3.17
Partial biochemical characterization of the activated esterase required in the complement-dependent chemotaxis of rabbit polymorphonuclear leukocytes. J Exp Med (1967) 3.15
The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med (1971) 2.95
Chemotoxis of mononuclear cells. J Exp Med (1968) 2.95
Involvement of platelet-endothelial cell adhesion molecule-1 in neutrophil recruitment in vivo. Science (1993) 2.71
The chemosuppression of chemotaxis. J Exp Med (1966) 2.62
Evidence for role of hydroxyl radical in complement and neutrophil-dependent tissue injury. J Clin Invest (1983) 2.52
Protective effects of C5a blockade in sepsis. Nat Med (1999) 2.50
Role of endothelial-leukocyte adhesion molecule 1 (ELAM-1) in neutrophil-mediated lung injury in rats. J Clin Invest (1991) 2.50
Tissue injury caused by deposition of immune complexes is L-arginine dependent. Proc Natl Acad Sci U S A (1991) 2.49
Neutrophil-dependent acute lung injury. Requirement for P-selectin (GMP-140). J Clin Invest (1992) 2.47
Role of oxygen metabolites in immune complex injury of lung. J Immunol (1981) 2.39
Tumor necrosis factor-alpha induction of novel gene products in human endothelial cells including a macrophage-specific chemotaxin. J Biol Chem (1990) 2.37
In vitro and in vivo activity of a lymphocyte and immune complex-dependent chemotactic factor for eosinophils. J Exp Med (1971) 2.36
Complement-derived leukotactic factors in inflammatory synovial fluids of humans. J Clin Invest (1971) 2.35
Neutrophil aggregation and swelling induced by chemotactic agents. J Immunol (1977) 2.26
Evidence for soluble immune complexes in the pathogenesis of the glomerulonephritis of quartan malaria. Lancet (1969) 2.22
C3 leukotactic factors produced by a tissue protease. J Exp Med (1969) 2.19
Human herpesvirus 6 in salivary glands. Lancet (1990) 2.15
Biochemical demonstration of the activatable esterase of the rabbit netrophil involved in the chemotactic response. J Immunol (1970) 2.12
In vivo damage of rat lungs by oxygen metabolites. J Clin Invest (1981) 2.10
In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest (1997) 2.04
Pulmonary endothelial cell killing by human neutrophils. Possible involvement of hydroxyl radical. Lab Invest (1985) 2.01
Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol (1979) 1.96
Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol (1996) 1.95
C5a-induced expression of P-selectin in endothelial cells. J Clin Invest (1994) 1.93
Chemotactic factor inactivator in normal human serum. J Clin Invest (1973) 1.93
Chemotactic factor influences on the aggregation, swelling, and foreign surface adhesiveness of human leukocytes. Am J Pathol (1978) 1.91
Generation of chemotactic activity in rabbit serum by plasminogen-streptokinase mixtures. J Exp Med (1967) 1.90
Leukotactic factors elaborated by virus-infected tissues. J Exp Med (1972) 1.89
Neutropenia induced by systemic infusion of chemotactic factors. J Immunol (1977) 1.89
Molecular and clinical correlations of deletions leading to Duchenne and Becker muscular dystrophies. Neurology (1989) 1.88
Defective regulation of inflammatory mediators in Hodgkin's disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med (1974) 1.88
Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest (1989) 1.86
Acute inflammatory pulmonary reactions induced by chemotactic factors. Am J Pathol (1979) 1.79
Impaired leucotactic responsiveness in a child with recurrent infections. Lancet (1969) 1.78
Selective neutrophil desensitization to chemotactic factors. J Cell Biol (1979) 1.77
Requirement and role of C5a in acute lung inflammatory injury in rats. J Clin Invest (1996) 1.77
Tumor necrosis factor alpha regulates in vivo intrapulmonary expression of ICAM-1. Am J Pathol (1993) 1.74
Leukotactic factors in health and disease. Am J Pathol (1971) 1.71
Impaired neutrophil chemotaxis in patients with juvenile and rapidly progressing periodontitis. J Periodontal Res (1979) 1.70
Inhibition of lung inflammatory reactions in rats by an anti-human IL-8 antibody. J Immunol (1993) 1.68
Neutrophil chemotactic factors and related clinical disorders. Arthritis Rheum (1970) 1.68
Molecular cloning and characterization of DEFCAP-L and -S, two isoforms of a novel member of the mammalian Ced-4 family of apoptosis proteins. J Biol Chem (2000) 1.66
Lung and dermal vascular injury produced by preformed immune complexes. Am Rev Respir Dis (1978) 1.64
Pathogenesis of the granulomatous lung diseases. Am Rev Respir Dis (1984) 1.64
C5 chemotactic fragment induces leukocyte production of tissue factor activity: a link between complement and coagulation. J Clin Invest (1979) 1.63
Isolation from human serum of an inactivator of bacterial lipopolysaccharide. Am J Pathol (1977) 1.58
Influence of inhibitors of cellular function on chemotactic factor-induced neutrophil aggregation. J Immunol (1977) 1.57
Two distinct chemotactic factor inactivators in human serum. J Immunol (1975) 1.55
Inhibition of in vivo and in vitro neutrophil responses to chemotactic factors by a competitive antagonist. J Immunol (1978) 1.55
Endothelial cell killing by neutrophils. Synergistic interaction of oxygen products and proteases. Am J Pathol (1989) 1.55
Chemotaxis of human eosinophils. Am J Pathol (1969) 1.54
Gastrointestinal milk intolerance of infancy. Am J Dis Child (1989) 1.54
Role of C5a in multiorgan failure during sepsis. J Immunol (2001) 1.53
Chemotaxis of rat lymphocytes. J Immunol (1977) 1.53
Enhancement by the complement membrane attack complex of tumor necrosis factor-alpha-induced endothelial cell expression of E-selectin and ICAM-1. J Immunol (1995) 1.53
Role of macrophage inflammatory protein-1 alpha (MIP-1 alpha) in acute lung injury in rats. J Immunol (1995) 1.52
Biologic role of complement products. Complement-derived leukotactic activity extractable from lesions of immunologic vasculitis. J Immunol (1972) 1.51
Leukotactic dystunction in sarcoidosis. Ann Intern Med (1976) 1.50
Suppression by superoxide dismutase of immune-complex--induced pulmonary alveolitis and dermal inflammation. Am J Pathol (1981) 1.50
Mediator-induced activation of xanthine oxidase in endothelial cells. FASEB J (1989) 1.49
Requirements for leukocyte adhesion molecules in nephrotoxic nephritis. J Clin Invest (1993) 1.49
Protective effects of anti-C5a in sepsis-induced thymocyte apoptosis. J Clin Invest (2000) 1.49
Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol (1997) 1.49
Chemoattractants of leukocytes, with special reference to lymphocytes. Fed Proc (1972) 1.48
Biochemical quantitation of the chemotactic factor inactivator activity in human serum. J Lab Clin Med (1979) 1.46
In vitro and in vivo stimulation of rat neutrophils and alveolar macrophages by immune complexes. Production of O-2 and H2O2. Am J Pathol (1983) 1.46
Congenital 21-hydroxylase deficiency as a new deletion mutation. Detection in a proband during subsequent prenatal diagnosis by HLA typing and DNA analysis. Hum Immunol (1992) 1.45
In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol (1999) 1.45
Protective effects of oligosaccharides in P-selectin-dependent lung injury. Nature (1993) 1.43
Mediators of ischemia-reperfusion injury of rat lung. Am J Pathol (1997) 1.43
Neutrophil-dependent, oxygen-radical mediated lung injury associated with acute pancreatitis. Ann Surg (1989) 1.43
Oxygen radical dependent lung damage following thermal injury of rat skin. J Trauma (1983) 1.41
Immune complex-induced lung and dermal vascular injury. Differing requirements for tumor necrosis factor-alpha and IL-1. J Immunol (1992) 1.41
Defective leukotaxis in patients with lepromatous leprosy. J Lab Clin Med (1976) 1.41
Chemotactic factor inactivators of human granulocytes. J Clin Invest (1977) 1.40
Evidence for the role of oxygen radicals in acute nephrotoxic nephritis. Lab Invest (1984) 1.40
Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. J Neuroimmunol (1995) 1.39
Those nasty radicals. West J Med (1986) 1.39
Biologic activity of extracts of delayed hypersensitivity skin reaction sites. Cell Immunol (1973) 1.39
Protective effects of IL-4 and IL-10 against immune complex-induced lung injury. J Immunol (1993) 1.38